New hope for patients when standard immunotherapy stops working
NCT ID NCT04375384
Summary
This study is testing if a drug called cetuximab can help control head and neck cancer that has returned or spread after standard immunotherapy has stopped working. It will involve about 38 adults who have already tried a PD-1 inhibitor drug. The main goal is to see if the cancer shrinks and for how long, while also carefully tracking side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.